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Androgens control male sexual development and maintenance of the adult male phenotype.They have very
divergent effects on their target organs like the reproductive organs, muscle, bone, brain and skin.This is
explained in part by the fact that different cell types respond differently to androgen stimulus, even when all
these responses are mediated by the same intracellular androgen receptor.To understand these tissue- and
cell-specific readouts of androgens, we have to learn the many different steps in the transcription activation
mechanisms of the androgen receptor (NR3C4). Like all nuclear receptors, the steroid receptors have a central
DNA-binding domain connected to a ligand-binding domain by a hinge region. In addition, all steroid receptors
have a relatively large amino-terminal domain. Despite the overall structural homology with other nuclear
receptors, the androgen receptor has several specific characteristics which will be discussed here.This
receptor can bind two types of androgen response elements (AREs): one type being similar to the classical
GRE/PRE-type elements, the other type being the more divergent and more selective AREs.The
hormone-binding domain has low intrinsic transactivation properties, a feature that correlates with the low
affinity of this domain for the canonical LxxLL-bearing coactivators. For the androgen receptor, transcriptional
activation involves the alternative recruitment of coactivators to different regions in the amino-terminal domain,
as well as the hinge region. Finally, a very strong ligand-induced interaction between the amino-terminal
domain and the ligand-binding domain of the androgen receptor seems to be involved in many aspects of its
function as a transcription factor.This review describes the current knowledge on the structure-function
relationships within the domains of the androgen receptor and tries to integrate the involvement of different
domains, subdomains and motifs in the functioning of this receptor as a transcription factor with tissue- and
cell-specific readouts.
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Introduction
Androgens are the male sex hormones that belong to the
steroid hormone family.They are mainly produced in
testes, ovaries and adrenals. In early life, testicular
androgens induce differentiation processes that lead to
the development of the male phenotype. During
adulthood, androgens remain essential for the
maintenance of the male reproductive function, as well
as a number of gender-dependent parameters like bone
and muscle mass, hair growth and behavior.
The androgenic steroid testosterone is the precursor for
the local synthesis of dihydrotestosterone, as well as
estrogens. Each of these hormones has specific functions
in the development and maintenance of the male
phenotype. Both testosterone and dihydrotestosterone
interact with the androgen receptor (AR or NR3C4), which
is a member of the nuclear receptor (NR) family [Evans,
1988].
The human AR is a protein of 919 amino acids in length,
but this can vary because it contains a poly-glutamine
and a poly-glycine stretch of variable lengths (Figure 1).
The protein migrates in a polyacrylamide gel
electrophoresis with an apparent molecular weight of 110
kDa. It is encoded by a single copy gene located on the
X-chromosome. Like all nuclear receptors, the AR has a
centrally-located DNA-binding domain (DBD) consisting
of two zinc-coordinated modules (Figure 2).
Carboxyl-terminally situated is the ligand-binding domain
(LBD), which provides the regulatory switch by which
androgens control the activity of the AR as a transcription
factor.The hinge region connects the DBD with the LBD.
It has different control functions which will be discussed
in greater detail.The amino-terminal domain (NTD) is
less conserved, both in size and sequence, between the
different NRs. Even between the different steroid
receptors, homology in this domain is only about 15%,
and comparative structural studies revealed little similarity
[McEwan et al., 2007].
For several nuclear receptors, a communication between
the ligand-binding domain and the amino-terminal domain
has been documented [He et al., 1999; Kraus et al., 1995;
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Review  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1. (A) Schematic representation of the androgen receptor with indications of its specific motifs and domains, and (B) the features
of the amino-terminus of the androgen receptor. (A) A schematic representation of the AR (top) and of a p160 steroid receptor coactivator (bottom)
is given with indications of the nuclear receptor-interacting domain (LxxLL) and the Tau-5-interacting domain (Qr). Arrows indicate possible inter- or
intramolecular interactions.The dotted line with arrowheads indicates the interference of Tau-1 on Tau-5.The sequence of the carboxyl-terminal
extension (CTE) is given in the box at the top.The acetylatable Lysine 630 is given in italic, the part of the nuclear localization signal is underscored.
The location of core Tau-1 is indicated. (B) The relative positions of Tau-1 and Tau-5 are indicated, together with: the 
23FQNLF
27-motif, the polyglutamine
(Qn), the polyproline (Pn) and the polyglycine (Gn) stretches.The sequences of the core Tau-1 overlapping motifs (see text) are given in the box on
the left, the features of Tau-5 discussed in the text are given in the box on the right: the 
433WHTLF
437 motif and the SUMO-ylation sites.
Langley et al., 1998; Metivier et al., 2001;Tetel et al.,
1999]. For the AR, this interaction is very strong.The
current knowledge and questions on its physiological
importance will be discussed.
Further clues on structure-function relationships within
the AR have been provided by the discovery of the links
between divergent diseases and mutations in the human
AR gene (summarized in http://androgendb.mcgill.ca/ for
overview).While germ line mutations have been detected
in androgen-insensitivity patients, a number of somatic
mutations have been linked with prostate cancer. In this
paper, we will discuss the specific roles of the DBD, LBD,
NTD and hinge region of the androgen receptor that
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Review Androgen receptor domainsFigure 2. (A) Crystal structure of the AR-DBD and consensus sequences of the classical AREs and selective AREs, and (B) the two Zn
finger coordinated modules of the DNA binding domain of the androgen receptor. (A) The top panel shows the crystal structure of the AR-DBD
bound to a direct repeat of 5'-TGTTCT-3' (PDB ID code 1R4I; Shaffer et al., 2004).This image was generated with the software PDB protein Workshop
1.50.The consensus sequences of the classical AREs and the selective AREs are given in the lower panel.This picture was obtained with the software
Weblogo3 (Crooks et al., 2004). Dotted lines indicate the stronger interactions with the 5'-AGAACA-3' hexamer on the left. (B) The single letter code
for amino acids is used.The P-box residues are indicated in green, the D-box residues in red and the nuclear localization signal in blue.The fragments
that are encoded by exon 2, exon 3 and part of exon 4 are given. CTE indicates the carboxyl terminal extension involved in DNA binding, intracellular
trafficking and transactivation.
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found in these diseases.
The androgen response elements
Steroid receptors have long been known to bind DNA
elements that are organized as inverted repeats of
hexameric binding sites separated by three nucleotide
spacers. For the estrogen receptors, the consensus
hexamer is 5'-TGACCT-3'. For androgen, glucocorticoid,
progestagen and mineralocorticoid receptors (AR, GR,
PR and MR, respectively), the consensus reads
5'-TGTTCT-3' [Cato et al., 1987; Ham et al., 1988]. Such
binding sequences have been described in
androgen-responsive genes and will be called here
classical androgen response elements (clAREs, Figure
2A).
In view of the high homology between the DNA-binding
domains and the similarity of the response elements, it
is not surprising, in vitro at least, that these response
elements are promiscuous for all four receptors.The AR,
however, holds a specific position within the group of
steroid receptors, since several selective AREs (selAREs,
Figure 2A) have been described that are not recognized
by the GR. Selective androgen-dependent
enhancers/promoters were first discovered near the rat
probasin gene, the sex-limited protein gene and the
secretory component gene [Adler et al., 1991; Rennie et
al., 1993;Verrijdt et al., 1999]. A consensus sequence
for these selAREs is given in Figure 2A. Based on the
sequence comparison of the selective AREs that were
described initially (PB-ARE-2:GGTTCTTGCAGTACT; SC
ARE: GGCTCTTTCAGTTCT; Slp HRE 2:
TGGTCAGCCAGTTCT), we speculated that the selective
AREs are organized as partial direct repeats rather than
inverted repeats of the same 5'-TGTTCT-3' motif.This
seems to be corroborated by the fact that substitutions
of e.g. an adenine for a thymine at position 12 (see Figure
2A) result in a loss of specificity of the androgen-selective
elements or enhancers [Adler et al., 1993; Kasper et al.,
1994;Verrijdt et al., 2000].
Surprisingly, all androgen-selective enhancers contain
promiscuous clAREs, as well as selective AREs.This
indicates a hierarchy among the AREs, and this hierarchy
was shown to depend on the topology of the enhancers,
since small insertions or inversions between the receptor
binding sites can result in a loss of selectivity [Adler et
al., 1993].
Furthermore, mutations in the sequence immediately
downstream of an ARE can also affect the functionality
of the element, even when little effect on in vitro affinity
of the AR-DBD was observed. Such experiments show
that flanking sequences have direct effects on DNA
recognition, as well as indirect, possibly allosteric effects
on the transactivation by the AR [Haelens et al., 2003;
Ham et al., 1988; Nelson et al., 1999].This explains for
instance the fact that even when in reporter constructs
the C3(1) ARE and the SC ARE are active, transferring
the two 5'-TGTTCT-3'-like hexamers of the SC ARE into
the surrounding sequence of the C3(1) ARE resulted in
a very weak ARE, even when the in vitro affinity for the
AR-DBD was unaffected [Haelens et al., 2007; Haelens
et al., 2003].
From earlier DNA-cellulose competition assays, we
learned that AR-binding DNA fragments are enriched in
5'-TGTTCT-3' motifs, but only a few of these were shown
to act as AREs in functional assays [Claessens et al.,
1990].These AR binding fragments contain complex
enhancers with monomer AR binding sites, but are also
enriched for binding sites for NF1, Sp1, Oct1 and Ets-like
transcription factors (reviewed in [Claessens et al., 2001]).
Since then, transcription factor binding studies have
benefited from the development of new techniques like
chromatin immunoprecipitation (ChIP), ChIP-on-chip and
ChIP-seq assays. An advantage of these techniques is
that binding of a transcription factor to its target DNA
sequences is studied in a cellular environment.
ChIP-on-chip data revealed that the AR binds to genomic
regions that contain DNA elements which are very similar
to the classical GRE consensus, but also to fragments
that contain AR-binding sequences that differ considerably
from this consensus and might consist of simple
5'-TGTTCT-3'-like monomer binding sites [Bolton et al.,
2007; Massie et al., 2007;Wang et al., 2007]. It has also
been possible to subdivide the putative AREs from a
ChIP-on-chip analysis into inverted repeat-like and direct
repeat-like elements, but further work is needed to prove
the functional importance of each of these sequences.
The novelty of the ChIP-on-chip and ChIP-seq data
resides in the fact that chromatin-embedded AR-binding
sites are characterized, while earlier AREs were
characterized by in vitro binding assays and transient
transfection assays. It will be interesting to see how the
AR interacts with these newly-described elements, and
what the consequences are of DNA/chromatin binding
on the functionality of the AR as a transcription factor.
The genomic fragments identified by ChIP-on-chip with
antibodies against AR seem to contain complex
enhancers with monomer AR binding sites, but are also
enriched for binding sites for GATA-2, Oct1 and Ets1,
thus enabling the unraveling of the hierarchical regulatory
networks that govern androgen-dependent gene
expression [Bolton et al., 2007; Massie et al., 2007;Wang
et al., 2007].These networks most likely will also involve
indirect DNA recruitment of the AR by other factors like
AP1, NFkB and GATA-factors, as well as direct effects
of the AR on expression of other transcription factors
[Bhardwaj et al., 2008; Heemers et al., 2006; Palvimo et
al., 1996]. Most recently, Lupien et al. [Lupien et al., 2008]
have shown that FoxA1 binding in the vicinity of AREs
primes the chromatin for binding by other transcription
factors like the AR and ER.
The DNA-binding domain
The DNA-binding domains of the nuclear receptors are
approximately 80 amino acids long and are organized in
two zinc fingers or modules in which zinc atoms are
coordinating four cysteines (Figure 2B). An α-helix in the
first zinc-coordinated module enters the major groove of
the hexameric motif (Figure 2A).The P-box residues
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identical for AR, GR, MR and PR.The second
zinc-coordinated module is involved in the
DNA-dependent dimerisation via the so-called D-box
residues (Figure 2B).These residues are also conserved
between AR, GR, MR and PR [Zilliacus et al., 1995]. In
analogy with the other steroid receptors, the DNA-binding
domain of the AR binds as a dimer to the classical AREs
([Shaffer et al., 2004] and Figure 1A).This dimerisation
fixes the position of the DNA-interacting residues of the
P-box, thus explaining how an inverted repeat of
5'-TGTTCT-3'-like motifs separated by exactly three
nucleotides is bound with high affinity.
The high evolutionary conservation of the DNA binding
by the steroid receptor explains why the DBD backbone
structures are superimposable.Why the selective AREs
are recognized by AR and not by GR is still a matter of
debate. On the one hand, biochemical analysis of the
DNA-binding domains has shown the usage of an
alternative dimerisation interface, distinct from the one
described for receptor binding to classical GRE/AREs
(reviewed in [Verrijdt et al., 2003]). On the other hand, in
a crystal structure of the AR-DBD on a direct repeat of
the 5'-TGTTCT-3', the two DBDs dimerise in a
head-to-head conformation similar to what has been
observed for GR, PR and ER [Luisi et al., 1991; Roemer
et al., 2006; Schwabe et al., 1990; Shaffer et al., 2004].
Interestingly, the AR dimerisation surface, as seen in the
crystal data, is enriched by an extended vanderWaals
surface and three supplementary hydrogen bonds.
However, swapping the residues involved between AR
and GR-DBDs did not affect DNA binding specificity, thus
contradicting the crystallization data [Verrijdt et al., 2006].
For other nuclear receptors, a dimerisation on direct
repeat elements has been documented as well. For the
VDR-DBD, an extension of the second zinc finger of one
monomer contacts the DBD that binds to the immediately
upstream hexamer [Shaffer and Gewirth, 2002]. Earlier
biochemical analyses also indicated an important role of
the carboxyl-terminal extension (CTE; Figure 2B) of the
AR-DBD in the recognition of selAREs [Haelens et al.,
2003; Schoenmakers et al., 1999; Schoenmakers et al.,
2000]. Unfortunately, as for the GR- and ER-DBDs, the
crystal data did not reveal the structure of this CTE. Only
for the PR DBD was this fragment visible, and it showed
non-specific interaction between an arginine residue in
the PR-CTE and the minor groove 3' of the 5'-TGTTCT-3'
hexamer [Roemer et al., 2006].
Overall, the AR seems to have the highest affinity for
DNA, mainly due to a stronger dimerisation.While the
GR and PR have weaker dimerisations, the PR is able
to bind monomeric binding sites through an extended
DNA-interaction surface [Roemer et al., 2006].Whether
a similarly extended DNA-interacting surface is also
present for the AR- and GR-DBD is still unclear, although
nucleotide substitutions 3' of AREs can have an effect on
binding and transactivation in transient assays [Haelens
et al., 2003; Ham et al., 1988].
To evaluate the physiological relevance of the selective
AREs, we developed a transgenic mouse model, called
SPARKI for ‘Specificity affecting AR Knock-In’. In these
mice, the exon encoding the second zinc finger of the AR
was replaced by the exon encoding the second zinc finger
of the GR.The encoded mutant AR lost high affinity for
selective AREs, while recognition of the classical AREs
remained unaffected. In male SPARKI mice, the
expression of some of the Sertoli cell and prostate-specific
androgen-regulated genes is differentially affected. For
the genes for which androgen control in SPARKI animals
is primarily affected, we have been able to define selective
AREs, while the less affected genes are controlled by
classical AREs [Moehren et al., 2008; Schauwaers et al.,
2007].
The phenotype of the SPARKI mouse model
demonstrates that the second zinc finger of the AR, and
by extension the selAREs, are not involved in the
androgen signaling in muscle and bone, nor does it
change circulating FSH, LH and testosterone levels.The
mutation severely affects the weight of organs and tissues
of the reproductive system like testis, prostate, epididymis
and seminal vesicles, while it does not affect the weight
of the Levator ani, or the lean body mass or the bone
mineral density of the animals.Therefore, the selAREs
seem to have clear system-specific effects. Further
analyses of the reproductive organs should lead to the
further identification of genes regulated via selAREs.
The hinge region
DNA binding and ligand binding involve two distinct
receptor domains, separated by a flexible linker, called
the hinge region.This hinge region can be defined as the
fragment between the last α-helix of the DNA-binding
domain and the first α-helix of the ligand binding domain
(from 623 to 671 for the human AR). After the cloning of
the first steroid receptor cDNAs, it became apparent that
the sequence of this hinge domain is poorly conserved,
although for all steroid receptors it contains a nuclear
localization signal (NLS) ([Evans, 1988; Zhou et al., 1994]
and Figure 2B).The AR-NLS binds to importin α, and
pathological mutations within the NLS that are associated
with prostate cancer and androgen-insensitivity syndrome
reduce the binding affinity [Cutress et al., 2008]. Aside
from this nuclear translocation signal, several other roles
for the hinge region in the control of AR activity are
emerging.
Ser 650
The AR hinge contains a serine at position 650 that can
be phosphorylated by MEKK-kinases and which seems
to be involved in the regulation of receptor translocation
[Gioeli et al., 2006; Kesler et al., 2007]. Indeed, a mutation
of Serine 650 to Alanine reduced the nuclear export of
the AR [Gioeli et al., 2006]. Recently, a germ line Serine
to Glycine mutation has been found in a fertility patient
with hypogonadism and scrotal hypoplasia [Zuccarello et
al., 2008]. A detailed comparative in vitro analysis
revealed a reduction of the activity of this mutant AR, but
the effect on nuclear export has not been evaluated.
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The hinge region harbors a putative PEST sequence. In
view of the recent implication of receptor degradation in
transcription [Kang et al., 2002; Lin et al., 2002; Metivier
et al., 2003], this would be an important function.
However, deletion of this putative PEST sequence did
not affect AR activity or its steady state levels [Haelens
et al., 2007].
Arg 629 and Lys 630
Somatic mutations of arginine 629 and lysine 630 have
been detected in prostate cancer biopsies, and these
mutations positively affect cell colony formation in
xenotransplants [Fu et al., 2003].What the functions of
these residues are and how these mutations could be
correlated with prostate cancer development has been
studied intensely.The lysine 630 has been reported to
be an in vitro target for acetylation by CBP/p300, p/CAF
and Tip60.These histone acetyltransferases also interact
with the AR hinge region and can coactivate the AR [Fu
et al., 2003; Fu et al., 2000; Gaughan et al., 2002].
However, the exact functional consequence of AR
acetylation is difficult to determine because of the multiple
roles of acetyltransferases in transcription and chromatin
restructuring on the one hand, and because lysine 630
is part of the nuclear translocation signal on the other.
Mutating the lysines in the nuclear localization signal
affects the intracellular location of the AR, as well as its
DNA binding, and has also been shown to increase or
prevent specific coregulator interactions, receptor folding
and receptor aggregation [Faus and Haendler, 2006;
Haelens et al., 2007;Thomas et al., 2004].
DNA binding
Part of the AR hinge region is also involved in high affinity
DNA binding (see above).While binding to classical AREs
only involves the two zinc coordinating modules (ending
at position 628 in the human AR), binding to selAREs
involves a carboxyl-terminal extension (CTE) up to
position 636. In addition, from mutation analysis of the
hinge region, it becomes increasingly clear that there is
no strict correlation between DNA-binding affinity and
transactivation [Haelens et al., 2007;Tanner et al., 2004].
The deletion or mutation of the 
629RKLKKLGN
636 motif,
which is part of the CTE (Figure 1A), results in an
apparent loss of in vitro DNA binding, as well as an
impairment of nuclear translocation, but the mutant AR
has an increased activity in ARE-mediated transcriptional
control.This apparent paradox certainly merits further
investigations, since it might provide new therapeutic
targets for prostate cancer treatment.
In summary, the hinge region was first described as
merely a flexible linker between the DBD and the LBD,
but now it is known to have an important input/output
function: it is involved in nuclear import and export, DNA
selectivity and affinity, and transactivation potential of the
AR.The underlying mechanisms remain elusive, but
several proteins have been reported to interact physically
or functionally with the hinge region.The group of Jänne
and Palvimo reported the interaction with Ubc9 and PIAS
(protein inhibitor of activated STAT) proteins [Poukka et
al., 2000]. Both proteins are involved in the sumoylation
of the AR-NTD (see below), as well as e.g. the SRC
coactivator family. Other coactivator complexes that
interact through the hinge region are the
BAF57-containing SWI/SNF complex and the p300/PCAF
complex [Garcia-Pedrero et al., 2006; Link et al., In Press;
Link et al., 2005].The small glutamine-rich
tetratricopeptide is a hsp70/hsp90 co-chaperone (SGT-1)
that interacts with the AR hinge region.This protein acts
on the androgen response outside the nucleus, keeping
the AR in the cytoplasm and thus regulating its activity
and its responsiveness to ligand [Buchanan et al., 2007].
Similar in vitro effects on ligand binding and intracellular
trafficking of AR have been described for the other
tetratricopeptide repeat proteins, FKBP51 and FKBP52.
However, knock-out experiments demonstrated an effect
of FKBP51 ablation on some, but not all,
androgen-regulated tissues, thus demonstrating the
tissue-specificity of the action mechanisms of these TRPs
[Yong et al., 2007].
Clearly, further structural data of the hinge region, as well
as further elucidation of its exact interacting domains
within the receptor itself or in coregulatory proteins will
help to clear up the exact mechanisms affecting the
activity of the androgen receptor.
The ligand-binding domain
The structure of the AR ligand-binding domain complexed
with a variety of ligands has been solved.Very similar to
what has been reported for other nuclear receptor LBDs,
it is organized as a twelve α-helical sandwich with a
central ligand-binding cavity [Matias et al., 2000; Sack et
al., 2001]. Eighteen residues of helix 3, 5 and 11 of the
AR LBD directly contact the bound ligand, but the many
mutations described in androgen insensitivity syndrome
patients, as well as prostate cancer biopsies, indicate
that the integrity of the whole ligand-binding domain is
necessary for correct ligand binding.
The general mechanism of nuclear receptor activation by
the binding of ligand involves a repositioning of helix 12
in such a way that the ligand-binding pocket is closed,
and a hydrophobic cleft is formed on the surface of the
LBD [Moras and Gronemeyer, 1998].This restructured
part of the LBD surface is synonymous to the earlier
described activation function-2 (AF-2) [Danielian et al.,
1992] and serves as a docking site for coactivators. For
all nuclear receptors, the hydrophobic cleft will be
recognized by the nuclear receptor signature
motif-bearing steroid receptor coactivators [Heery et al.,
1997]. However, in a comparative study of a series of
these LxxLL-motifs derived from the NR coactivators,
only one interacted with high affinity with the isolated
AR-LBD, illustrating a different sequence-specificity of
the AR-LBD [Chang et al., 1999].This might explain why
the AR-AF-2 was so weak when tested in isolation
[Jenster et al., 1995].
When analyzed in more detail, the AR-AF-2 cleft differs
from that of other nuclear receptors in that it is able to
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23FQNLF
27-motif in the AR-NTD [Dubbink et al., 2004;
Hur et al., 2004]. Moreover, the hydrophobic cleft is
surrounded by a charged clamp formed by Lysine 720
and Glutamate 897, which can make backbone contact
with such FxxLF-motifs, but not with LxxLL-motifs.
The fact that canonical LxxLL-bearing coactivators have
a low affinity for the isolated AR-LBD was contradicted
by the strong AR coactivation by the SRC/p160
coactivators that include SRC-1, GRIP1/TIF2, and
AIB1/ACTR/TRAM-1. An explanation came from
experiments that demonstrated interaction and
coactivation of the isolated AR-AF1 by the same
SRC/p160s (see below).
The ligand-binding domain not only interacts with
testosterone and dihydrotestosterone, but also with a
number of steroidal and non-steroidal agonists and
antagonists [Gao and Dalton, 2007]. Surprisingly, all
agonist-bound structures are nearly superimposable,
even when in vivo they have distinct effects. Obviously,
the in vivo differences could be due to ligand metabolism
or differential expression of AR-interacting proteins, or
alternatively, the reported structural similarities reflect
limitations of the crystallization experiments. Alternatively,
a more detailed comparison might reveal some minor
variations in structure with important allosteric effects on
e.g. coactivator binding, like those documented for
testosterone and dihydrotestosterone [Askew et al., 2007].
Recently, Estébanez-Perpiñá et al. [Estebanez-Perpina
et al., 2007] postulated an alternative binding site for
(ant-)agonists at the surface of the AR-LBD, different from
the AF-2 forming hydrophobic cleft. How such compounds
can affect AR activity is still unclear, but obviously such
new features of the AR-LBD can become important
targets for alternative and more selective (ant-)agonists.
The amino-terminal domain
The NTDs of the steroid receptors are clearly very
divergent in length, amino acid composition, as well as
the role they play in transcription transactivation
processes.The AR in particular depends on multiple
contributions from this NTD, even when the LBD provides
the necessary hormone control switch.
In contrast to the DBDs and the LBDs of the nuclear
receptors, no crystallographic or NMR-based structure
has been obtained for the NTDs, or fragments of it.This
is likely due to the lack of a tightly folded structure or the
existence of alternative structures [McEwan et al., 2007].
In spite of this, several motifs and structures have been
identified as binding sites for interacting partners or sites
for posttranslational modifications. An overview of what
is known on the AR-NTD is given in the following
paragraphs and in Figure 1B.
Transcription activation unit-1
Since the activation potential of the AR-LBD when tested
in isolation is weak (see above), the AR-NTD (called
AF-1) is considered to be the major activation domain of
the AR. Jenster et al. [Jenster et al., 1995] defined the
two transcription activation units, Tau-1 and Tau-5, within
AR-AF1.The group of Rennie identified two other
transactivation regions in the rat AR-NTD, designated
AF-1a and AF-1b, respectively [Chamberlain et al., 1996].
While AF-1b does not seem to be conserved in the human
AR, later studies have confirmed AF-1a as part of a
functional motif within the boundaries of Tau-1. Different
studies have ascribed functionality to motifs that overlap
with AF1a.They were named the 
179LKDIL
183 motif [He
et al., 2000], the 
183L/HX7LL
192 motif [Zhu et al., 2006] and
the core Tau-1 between residues 177 and 203
([Callewaert et al., 2006]and Figure 2).
The 
179LKDIL
183-motif was picked up during a search for
LxxLL-like motifs that might be involved in the interactions
between the AR-NTD and the AR-LBD. However, its
affinity for the AR-LBD is very weak and most likely not
significant [Alen et al., 1999; Steketee et al., 2002]. By
contrast, another LxxLL-like motif is necessary and
sufficient to explain this interaction (
23FQNLF
27, see
below).
Mutation analysis of putative α-helices in Tau-1 resulted
in the description of the so-called core Tau-1 between
amino acids 173 and 203 in the human AR. Both the
hydrophobic side chains and the negative charges of this
amphipathic helix are important for the transactivating
capacity of the AR. It is also a strong autonomous
activation function, for which the coactivator partners
remain to be discovered [Callewaert et al., 2006].
The 
183L/HX7LL
192 motif has been proposed to serve as
a binding site for Tab2, a component of a NCoR repressor
complex [Zhu et al., 2006]. Binding of antagonists to the
AR triggers the recruitment of the Tab2/NCoR complex
and leads to the repression of AR-regulated genes.
However, in the presence of IL-1β, Tab2 is
phosphorylated by the MEKK1 pathway, which causes
the dissociation of the NCoR complex. In this way, the
equilibrium between coactivator binding and corepressor
binding to the AR is shifted so that the transcriptional
outcome can be positive, even when the AR-LBD is bound
by antagonist.This suggests a possible mechanism for
antagonists gaining characteristics of agonists, which is
also observed in prostate cancers after relapse of patients
treated with these antagonists. Of course, other
mechanisms that might explain such relapses are
mutations in the AR that change its ligand-specificity
[Taplin and Balk, 2004], overexpression of coactivators
or loss of corepressors [Bevan, 2005] or changes in the
androgen effects on cell cycle progression [Balk and
Knudsen, 2008].
The region around core Tau-1 was also shown to acquire
a more folded conformation when interacting with
fragments of the SRC coactivator family or of the RAP47
subunit of the general transcription factor TFIIF [Betney
and McEwan, 2003; McEwan and Gustafsson, 1997;
McEwan et al., 2007]. It is proposed that this induced
structure is the active conformation of AR-AF1, because
mutations that disrupt the α-helical structure lead to a
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with RAP47.
Another motif that does not overlap with, but is very close
to AF1a, is the 
234AKELCKAVSVSMGL
247 motif
immediately carboxyl-terminal of core Tau-1.This
sequence is highly conserved in the AR from mammals
to fish and is the interaction site for the Hsp70-interacting
protein E3 ligase CHIP [He et al., 2004a], the
overexpression of which downregulates the steady state
levels of AR.
Interestingly, mutations in both core Tau-1 and the
CHIP-interacting motif have been described in prostate
cancer biopsies.The mutation K179R has been described
in a primary prostate cancer biopsy, and the A197G
mutation was described in a prostate cancer sample of
a patient treated with bicalutamide [Tilley et al., 1996].
Moreover, two mutations in the CHIP-interacting motif,
A234T and E236G, were detected in tumors that arose
in the TRAMP model of prostate cancer [Han et al., 2001].
When tested in vitro, all four mutations gave rise to a
more active AR [Callewaert et al., 2006; Han et al., 2001],
and the E236G mutation induces metastatic prostate
cancer very efficiently when introduced in a transgenic
model [Han et al., 2005].
Transcription activation unit-5
The size and locations of the activation functions in use
by the AR seem to vary depending on the presence of
the AR-LBD or the AR-DBD, as well as on the nature of
the reporter genes tested [Alen et al., 1999; Callewaert
et al., 2006; Jenster et al., 1995].Tau-5 is the fragment
of the AR-AF-1 described by Jenster et al. [Jenster et al.,
1995] that retains the activation potential in the absence
of the LBD, while Tau-1 was more dependent on the
presence of the LBD.Tau-5 covers residues from
positions 360 to 528. It is an autonomous activation
domain, which is targeted by several proteins. Most
importantly, it strongly interacts with a glutamine-rich
domain of the SRC/p160 coactivators [Alen et al., 1999;
Bevan et al., 1999; Irvine et al., 2000]. Since the affinity
of the LxxLL motifs of the SRC/p160s for the AR-AF-2 is
low, the Tau-5 region is considered to be the major
interaction site for the SRC/p160 coactivators [Bevan et
al., 1999; Christiaens et al., 2002].
Tau-5 has also been defined as the target for the RhoA
effector protein kinase C-related kinase PRK1 [Metzger
et al., 2003]. Stimulation of the PRK1 signaling cascade
results in a ligand-dependent superactivation of the AR,
which might be the result of an enhanced association
with the SRC/p160s.
The integrity of the complete Tau-5 is required for its
optimal autonomous activation function, since any deletion
affects its transactivation properties and its interaction
with the SRC/p160s [Callewaert et al., 2006]. Possibly,
Tau-5 is a globular domain rather than a molted globule
or an extended domain containing one or more motifs,
like what has been described for the AF-1 fragment, which
partly overlaps with Tau-1 and Tau-5 [McEwan et al.,
2007].
The only motif that is described thus far in Tau-5 is the
433WHTLF
437 motif that was first proposed as an interaction
site for the liganded AR-LBD, again because of its
resemblance to the LxxLL-motif [Alen et al., 1999; He et
al., 2000].While this motif is not involved in these N/C
interactions, it plays a role in the ligand-independent
actions of AR in refractory prostate cancer. Its function
in ligand-dependent AR actions seems limited, however,
although the AR fragment from 426 to 446 can act as an
autonomous activation domain [Dehm and Tindall, 2007].
Several steroid receptors, as well as coactivators and
histones, have been reported to be conjugated with
SUMO-1. SUMO-ylation of the AR, GR and MR is
probably linked with repression of transactivation
potential, but the effect appears to be promoter- or
enhancer-specific (reviewed in [Faus and Haendler, 2006]
and [Leader et al., 2006]).The AR-NTD has two SUMO-1
modification sites in Tau-5 at positions 385 and 511,
respectively. AR SUMO-ylation is responsive to agonists,
but is not induced by the pure antagonist
hydroxyflutamide. Mutation of K385 clearly affects the
cooperativity of the receptor on complex hormone
response elements [Callewaert et al., 2004; Poukka et
al., 2000], similar to what has been shown for other
transcription factors [Iniguez-Lluhi and Pearce, 2000], but
how the SUMO-ylation at K385 determines the magnitude
of the receptor-dependent transcription responses
remains obscure.
Interplay between Tau-1 and Tau-5
Both Tau-1 (as described above) and Tau-5 are
necessary and sufficient for the intrinsic activity of the
AR-NTD and the full activity of the AR [Callewaert et al.,
2006]. Indeed, when Tau-1 and Tau-5 mutations are
introduced in the full length AR, it becomes completely
inactive.
Interestingly, some mutations in Tau-1 affect the
recruitment of the SRC/p160 coactivators through Tau-5.
Since there is no direct interaction of core Tau-1 with
SRC1, and since there is no evidence for direct
interactions between Tau-1 and Tau-5, this effect is likely
to be indirect, e.g. via induction of a conformational
change, or the recruitment of (a) secondary interaction
partner(s).
The polymorphic glutamine and glycine repeats
of the AR-NTD
The polymorphic CAG repeat in the AR gene encodes a
poly-glutamine-stretch (starts at position 57) that can vary
in length.The length ranges from 9-36 residues, with a
highest frequency of approximately 20. Epidemiological
studies have reported weak correlations between the
CAG repeat number and the risk of developing prostate
cancer, but the evidence for the implication of an
extension of the poly-glutamine tract in the etiology of
Kennedy’s disease is undeniable [Casella et al., 2001;
Ferro et al., 2002; La Spada et al., 1991].The CAG repeat
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aggressiveness of this disease. In a mouse model with
humanized AR-NTD, an extended glutamine tract resulted
in myopathic features similar to those known for
Kennedy’s disease, which suggests a role for muscle in
the non-cell autonomous toxicity of motor neurons [Yu et
al., 2006].This pathologic effect seems unrelated to the
general function of the AR as a transcription factor, but
rather may be the consequence of a gain-of-function of
the mutated receptor.
Mononen et al. [Mononen et al., 2002] described a
correlation between CAG repeat length and prostate
cancer risk. On the other hand, Sircar et al. [Sircar et al.,
2007] described a shortening of the CAG repeats in
genomic DNA derived from prostate cancer lesions.This
is an important finding, correlating an enhanced AR
activity to prostate cancer development. Indeed, earlier
in vitro studies showed that ARs with shorter or no
glutamine stretch are more potent transcription factors.
An enhanced interaction of the AR-NTD with the
SRC/p160s has been proposed as a possible explanation
[Buchanan et al., 2004; Callewaert et al., 2003a;
Chamberlain et al., 1994; Irvine et al., 2000]. Again,
depending on the reporter gene tested, this effect can be
more or less significant.
Besides the glutamine stretch, a glycine stretch (starting
at position 449, Figure 1B) within Tau-5 varies in length,
ranging from 10 to 30 residues. Its length variations might
also be correlated weakly with the incidence of diseases.
There are several studies which indicate that a short GGN
repeat may be a risk factor for the development of
prostate cancer [Ding et al., 2005]. Recently, a
combination of a short glycine stretch with a long
glutamine stretch, combined with an A645D substitution
in the hinge region, has been postulated to contribute to
the development of a case of androgen insensitivity
[Werner et al., 2006].
The 
23FQNLF
27-motif and the N/C interactions
Subsequent to the observation that there was a strong
N/C interaction between the NTD and the LBD of the AR,
several candidate motifs were tested for their possible
involvement in this process.The strongest LBD-interacting
motif clearly is the 
23FQNLF
27 motif at position 23, which
is highly conserved among the AR of different species
[Alen et al., 1999; Berrevoets et al., 1998; He et al.,
2004b; Langley et al., 1998; Steketee et al., 2002].
Deletion or mutation of the 
23FQNLF
27 motif and flanking
residues abrogates the N/C interaction, affect
transactivation by the AR in transient transfections and
change the kinetics of ligand-binding [He et al., 2004b].
Surprisingly, the functional importance of the N/C
interactions seems to be dependent on the nature of the
enhancer [Callewaert et al., 2003b].
23FQNLF
27-like
signature motifs have also been described in some of the
AR-interacting proteins such as ARA54 and ARA70 [He
et al., 2002; Heinlein and Chang, 2002; van de Wijngaart
et al., 2006].The hormone-dependent interaction of the
FxxLF motif-containing ARA70 and ARA54 with the AR
LBD has been demonstrated in vitro and in vivo, but their
role in transcription remains controversial [Alen et al.,
1999; Brooke et al., 2008;Toumazou et al., 2007; van
Royen et al., 2007].
Several lines of evidence also point to the possibility of
indirect N/C interactions mediated by the SRC/p160
steroid receptor coactivators [Berrevoets et al., 1998;
Ikonen et al., 1997; Shen et al., 2005]. Similar to what
was described for the estrogen receptor-α [Webb et al.,
1998], the LBD of the AR has some affinity for LxxLL-like
motifs, while the NTD is bound by a glutamine-rich region
of the SRC/p160s, suggesting that the p160s act as
bridging factors [Ma et al., 1999]. Conversely, some of
the AR corepressors seem to inhibit the N/C interactions
in the AR, but the exact implication of this on AR action
remains unclear [Burd et al., 2005; Liao et al., 2003].
In living cells, the N/C interaction is induced by ligand in
the cytoplasm [van Royen et al., 2007]. Once in the
nucleus, the AR distributes between a fast moving fraction
and fractions retained in speckles. Interestingly, no N/C
interaction is detectable in these speckles [van Royen et
al., 2007]. Since at least part of the speckles are active
in transcription, this indicates that the AR does not have
a closed conformation the whole time it occupies the
enhancers in the chromatin. By contrast, Klokk et al.
[Klokk et al., 2007] demonstrated intramolecular N/C
interactions when the AR is bound to an array of the
MMTV promoter in living cells. Also, Wong and
co-workers showed that N/C interactions are necessary
for full AR activity on chromatinized templates. [Li et al.,
2006].
In conclusion, the N/C interactions of the AR, as well as
the interactions of the NTD and LBD with their
coregulators, seem much more dynamic than originally
thought. Most likely, the interactions change during one
or more of the steps in the transcription activation cycles,
as described by the group of Gannon [Metivier et al.,
2003].When the N/C clamp opens, alternative surfaces
on the LBD, as well as the NTD, are expected to become
available for the interaction with proteins involved in
receptor turnover, nuclear translocation, nuclear mobility,
chromatin-modification, transcriptional regulation, etc.
General conclusions
The androgen receptor is a member of the nuclear
receptor family. Compared to most other members, the
AR has many similarities, but also many differences in
its mode of action. Most striking, is the absence of a
strong activation function in the ligand binding domain,
but this is compensated for by the presence of strong
activation functions in the NTD, one of which recruits the
same SRC/p160 coactivators as the canonical NR-AF-2.
The current challenges surrounding research on NR
action in general, and AR action in particular, are many.
Indeed, the action of the AR seems to depend on the
interplay between many motifs and domains that all seem
to have more than one specific function. For instance, at
least in vitro, the AR can dimerise through interactions
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interactions. However, at present it is still unclear whether
the N/C interactions happen intra- or intermolecularly, or
both.What signals drive the dimerisations and the
opening and closing of the N/C interactions of the AR,
and when the different alternative interactions take place,
remain largely unexplored. As a consequence, knowledge
on the spatio-temporal control of the communications of
the AR with other coactivators and transcription factors,
and their chronological sequence in the transcriptional
control by androgens in a cellular environment, is at its
infancy. Furthermore, these studies of biochemical and
cellular AR behavior will need to be substantiated further
by in vivo models, like the tissue-specific knock-out
models of AR or its coactivators, or specific knock-in
models resulting in deletions or mutations of specific AR
motifs or domains (cf. SPARKI model). Ultimately, these
should help to establish links between diverse
observations, such as the role of FoxA1 in interpretation
of the histone code [Lupien et al., 2008], the
spatio-temporal control of enhancer binding by NRs in
the nucleus [Nunez et al., 2008], and the intranuclear
behavior of AR and AREs in vivo [Klokk et al., 2007; van
Royen et al., 2007].
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